Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...
Things are going from bad to worse for Sarepta Therapeutics (NASDAQ: SRPT), a biotech focusing on gene therapies. The company ...
Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price lowered by Scotiabank from $105.00 to $80.00 in a ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report)’s stock price traded down 4% during trading on Thursday after ...
The Company is currently analyzing the case and will update the prescribing information for Elevidys to note this development.
Stocktwits on MSN2d
Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Giving UpShares of Sarepta Therapeutics Inc. have lost more than 26% this week, heading for their worst such performance in over a ...
AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...
Sarepta stock may recover sharply as additional information and data reveal that the adverse event reported by the company is ...
A patient has died while receiving Elevidys, a gene therapy for Duchenne muscular dystrophy, marking the first known death ...
The firm's stock price dropped 27 percent on Tuesday following the news that the young man died from acute liver failure after getting Elevidys.
Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that ...
Cambridge, Mass.-based Sarepta Therapeutics reported the first known death from its Duchenne muscular dystrophy gene therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback